Patricia L Allen bought $500K of Zenas BioPharma (ZBIO)
Executed Feb 12, disclosed Feb 13, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Feb 13), the stock returned -9.3% (delay-adjusted); from the execution session (Feb 12), +3.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Patricia L Allen (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Zenas BioPharma, Inc. (ZBIO). Across 1 priced purchase filing, the average 21-session return was +3.3% from execution and -9.3% from disclosure (delay-adjusted; derived). The largest single filing was $500K of ZBIO (19,860 sh across 4 lots, as filed), executed Feb 12.
Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→